Hikma Expands Ohio Plants With $267 Million Investment
Jordanian-founded drugmaker Hikma Pharmaceuticals is spending $267 million to expand its facilities in Columbus and Bedford.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you think big drug manufacturers expanding local plants helps lower your family's medicine costs?
Hikma Pharmaceuticals has invested $267 million to expand its manufacturing facilities in Columbus and Bedford. The White House has recognized the investment, and Congressman Mike Carey toured the expanded production lines at the Columbus site.
Why it matters
The expansion adds manufacturing capacity for generic medicines in Ohio and is projected to create 350 new jobs. It reflects continued investment in domestic pharmaceutical production in the Columbus area.
Hikma's $267 million investment is directed at its Columbus and Bedford sites, with 350 new jobs projected from the expansion. The breakdown of spending between the two locations was not provided.
The players
Hikma Pharmaceuticals
A Jordanian-founded pharmaceutical company that manufactures generic medicines and operates facilities in the United States.
Mike Carey
A U.S. Congressman representing Ohio who visited Hikma's Columbus manufacturing facility during the tour.
The details
Hikma expanded production through a new wing at its Columbus facility, whose groundbreaking took place sixteen months before Congressman Mike Carey visited the plant. During the visit, Carey met with employees and toured the expanded production lines where the company manufactures generic medicines.
Timeline
Sixteen months before the visit: groundbreaking of the new Columbus wing.
Recent visit: Congressman Mike Carey toured the Columbus facility.
Industry Trend
Hikma's expansion extends a trend of foreign-founded drugmakers expanding domestic generic medicine manufacturing in the United States. The White House's recognition of the investment places it within broader federal interest in onshoring pharmaceutical production.
The expansion is expected to create 350 new jobs in the Columbus area, which may offer employment opportunities to local workers. The added production capacity could affect the availability of generic medicines made at the Ohio plant.
The takeaway
Expanded domestic production of generic medicines can strengthen local manufacturing employment while adding capacity for everyday prescription drugs. Readers tracking pharmaceutical supply in Ohio may watch for the 2027 completion of the Columbus wing.
What happens next
The new wing of Hikma's Columbus facility is expected to be fully operational next year, in 2027.
Further reading
For more on the industry behind this expansion, see Healthcare coverage.
Source note: This article includes information reported by وكاله عمون الاخباريه.
Live Poll
Do you think big drug manufacturers expanding local plants helps lower your family's medicine costs?
